<a href="https://laohu8.com/S/MNPR">Monopar Therapeutics</a> reports third quarter net loss of $3.4 million
Monopar Therapeutics Inc. reported a net loss of $3.4 million, or $0.48 per share, for the third quarter of 2025, compared to a net loss of $1.3 million, or $0.37 per share, for the same period in 2024. As of September 30, 2025, the company held $143.7 million in cash, cash equivalents, and investments. Recent business developments include FDA clearance of an IND application for MNPR-101-Lu, a Phase 1 trial for advanced or metastatic solid tumors, and preparations to submit a New Drug Application for ALXN1840 for Wilson disease in early 2026. The company also completed a share repurchase of 550,229 shares from Tactic Pharma for $35 million, following a public offering, resulting in net proceeds of approximately $91.9 million before expenses.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9574781-en) on November 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.